Protagonist Therapeutics (PTGX) Income from Non-Controlling Interests (2016 - 2017)

Protagonist Therapeutics (PTGX) reported Income from Non-Controlling Interests of $11000.0 for Q2 2017, up 1200.0% on a YoY basis from $846.15 in Q2 2016, and up 178.57% sequentially from -$14000.0 in Q1 2017.

Protagonist Therapeutics (PTGX) Income from Non-Controlling Interests (2016 - 2017) Analysis & Trends

Protagonist Therapeutics (PTGX) has 2 years of Income from Non-Controlling Interests data on file, last reported at $11000.0 in Q2 2017.

  • For the quarter ending Q2 2017, Income from Non-Controlling Interests rose 1200.0% year-over-year to $11000.0; the trailing twelve-month figure through Jun 2017 stood at -$74000.0 (changed N/A YoY), and the FY2016 full-year result was -$67000.0, down 1240.0% from the prior year.
  • Income from Non-Controlling Interests advanced to $11000.0 in Q2 2017, from -$14000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $11000.0 in Q2 2017 to a low of -$72000.0 in Q4 2016.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 65,839.48 Bn 65,839.20 Bn - -
2 Nanobiotix 1,914.07 Bn 1,914.01 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 468.11 Bn 463.32 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 122.48 Bn 115.23 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 70.30 Bn 61.55 Bn 3.31 Bn -
7 Belite Bio 62.77 Bn 62.77 Bn - -
8 Argenx Se 55.66 Bn 50.47 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.42 Bn 34.41 Bn 959.66 Mn -
10 Protagonist Therapeutics 8.91 Bn 8.91 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2017 11,000.00
Mar 31, 2017 -14,000.00
Dec 31, 2016 -72,000.00
Sep 30, 2016 1,000.00
Jun 30, 2016 -1,000.00
Mar 31, 2016 5,000.00